Clinical Applications of ctDNA in Breast Cancer Diagnosis and Manage…

University of Miami Sylvester Comprehensive Cancer Center

D. Tripathy

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

Emerging Treatment Options for AML in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

A. Perl

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

2024 ASCO® Annual Meeting Insights Hub

V. Subbiah

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Total Health

S. Kazmi

Administration and Dosing of Tagraxofusp for BPDCN

Emanuele Angelucci

BPDCN: Current and Future Directions

Icahn School of Medicine at Mount Sinai

N. Pemmaraju

Endocrine Adverse Events From Checkpoint Inhibitors

Yale Cancer Center

K. Herold

ESMO 2024 Summary: The Emerging Global Epidemic of Early-Onset Cance…

2024 ESMO Annual Meeting Insights Hub

S. Ogino

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

Integrating Targeted Therapies in AML

Icahn School of Medicine at Mount Sinai

H. Kantarjian

Visible vs. Invisible Cancers - The Genomics and Natural History

Laurence Klotz

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+ Sol…

UCSF School of Medicine

H. Kang

Immunotherapies in Acute Leukemias: 2024 Update

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

C. Lai

Diagnostics in Lung Cancer: A Comprehensive Discussion - Best of Lun…

Total Health

T. Boyle